Introduction
============

The westernization of Chinese lifestyle has created recent trends toward decreased physical activity, increased life expectancy, and an increased incidence of colorectal cancer.[@b1-cmar-10-2581] Studies have demonstrated that approximately one-half of colorectal cancers develop liver metastases, and surgical resection is the primary treatment for colorectal liver metastases (CRLM).[@b2-cmar-10-2581]--[@b4-cmar-10-2581] A large number of studies have revealed that the 5-year overall survival rate is 30%--60% among patients who undergo radical resection for CRLM, and good long-term survival can be achieved using open hepatectomy for CRLM.[@b5-cmar-10-2581]--[@b7-cmar-10-2581] However, \~70% of patients with CRLM are ≥65 years old when they seek treatment, and elderly patients may be less able to tolerate hepatectomy (versus younger patients), which has led some surgeons to reject hepatectomy for elderly patients.[@b5-cmar-10-2581]--[@b8-cmar-10-2581]

The first reported laparoscopic hepatectomy (LH) was performed in 1992,[@b9-cmar-10-2581] and a growing number of reports have described LH treatment for CRLM.[@b10-cmar-10-2581]--[@b15-cmar-10-2581] Compared to open hepatectomy, LH for CRLM leads to lesser intraoperative blood loss, shorter hospital stays, similar or lower incidences of complications, and similar long-term outcomes.[@b10-cmar-10-2581]--[@b15-cmar-10-2581] However, the previous studies have not included large numbers of elderly patients, and only a few English reports have described LH treatment for CRLM.[@b16-cmar-10-2581]--[@b19-cmar-10-2581] Furthermore, there is a lack of studies comparing short- and long-term outcomes of LH treatment between elderly and middle-aged patients with CRLM. Therefore, the present study aimed to compare the short- and long-term outcomes of LH treatment among elderly and middle-aged patients with CRLM.

Patients and methods
====================

This study complied with the Declaration of Helsinki rules. This retrospective research was approved by the Ethics Committee of First Hospital, JiLin University. The need for informed consent from all patients was waived because this was a retrospective study. All data had no personal identifiers and were kept confidential.

Between January 2009 and January 2016, 241 consecutive patients underwent LH treatment for CRLM and were considered eligible for this retrospective study. The inclusion criteria were as follows: 1) the patient was undergoing their first hepatectomy, 2) the patient had undergone radical resection of colorectal cancer, and 3) complete clinical and follow-up data were available for the patient. The exclusion criteria were as follows: 1) repeat hepatectomy and 2) palliative hepatectomy. Based on their age at the LH, the patients were divided into an elderly group (≥70 years old, 78 patients) and a middle-aged group (60--69 years old, 163 patients). The location, number, diameter, and operability of liver metastatic lesions were preoperatively confirmed in all patients using tumor biomarkers, abdominal computed tomography or magnetic resonance imaging, and other examinations. Positron emission tomography--computed tomography was performed as needed. Lung function tests, electrocardiography, echocardiography, and other examinations were performed to determine the patients' preoperative cardiopulmonary function. All patients were operated using the totally laparoscopic technique, and intraoperative ultrasonography was performed in all cases. The LH was performed according to a previous report.[@b19-cmar-10-2581] All LHs were carried out by the surgeon Dr Zhenhua Kang. Before this study, he had successfully completed 50 LH surgeries.

The Clavien--Dindo criteria were used to classify the severity of postoperative 90-day complications. Minor complications were defined as grades I--II and major complications as grades III--V. Postoperative 90-day mortality was defined as any death from oncological or non-oncological causes within 90 days after surgery.

After the patients were discharged, follow-ups were performed at outpatient clinics, the patient's house, community health service centers, and other locations. The follow-ups were performed every 3 months during the first year after surgery, every 4 months during the second year, every 6 months during the third year, and annually thereafter. Patients were referred for in-hospital treatment if tumor recurrence was suspected at any time. The follow-up rate was 100%, as all patients lived near our hospital, and the last follow-up was performed on May 31, 2017.

All the statistical analyses were performed using SPSS, Version 14.0 (SPSS Inc., Chicago, IL, USA). Normally distributed variables were analyzed by Student's *t*-tests and presented as mean and SD. Non-normally distributed variables were analyzed by Mann--Whitney *U* test and presented as medians and ranges. Differences between semiquantitative results were analyzed by Mann--Whitney *U* tests. Differences between qualitative results were analyzed by chi-square or Fisher's exact tests, as appropriate. Survival rates were analyzed by the Kaplan--Meier method, and differences between the two groups were analyzed by log-rank test. Multivariable Cox regression analysis was performed to identify the factors predictive of poor disease-free survival and overall survival by using both forward and backward stepwise selection. Explanatory variables with univariate *P* values ≤0.100 were included in the multivariable analysis. The results are reported as hazard ratios with 95% CIs. A level of 5% was set as the criterion for statistical significance.

Results
=======

The patients' general preoperative characteristics are shown in [Table 1](#t1-cmar-10-2581){ref-type="table"}. Compared to the middle-aged group, the elderly group had significantly higher values for Charlson comorbidity index, proportion of preoperative chemotherapy, and the American Society of Anesthesiologists score. No other significant differences were observed in the other preoperative characteristics (e.g., gender, body mass index, TNM stage, pre-LH carcinoembryonic antigen levels, and location of liver metastases).

The patients' short-term prognoses are shown in [Table 2](#t2-cmar-10-2581){ref-type="table"}. Both groups underwent similar surgical procedures, with most patients undergoing wedge resection or sectionectomy and a few patients undergoing left lateral sectionectomy. No significant inter-group differences were observed in the surgical times, intraoperative blood losses, intraoperative and postoperative blood transfusion rates, or incidences and severities of postoperative complications. The elderly group had a higher rate of conversion to open hepatectomy, and conversion in both groups was primarily related to bleeding. There were no intraoperative deaths in either group, although one patient in the elderly group died within 90 days because of liver failure and one patient in the middle-aged group died after 2 months because of metastasis to the central nervous system. Both groups had similar pathology results.

The median follow-ups for the elderly and middle-aged groups were 31 and 34 months, respectively, and this difference was not statistically significant (*P*=0.387). During the follow-ups, 32 patients in the elderly group died because of recurrence (n=29), ischemic stroke (n=1), hemorrhagic stroke (n=1), and sudden cardiac death (n=1), as shown in [Table 3](#t3-cmar-10-2581){ref-type="table"}. Fifty-three patients in the middle-aged group died because of recurrence (n=48) and non-cancer-related diseases (n=5). There were no significant inter-group differences in the recurrence locations, median time to recurrence, or other factors ([Table 3](#t3-cmar-10-2581){ref-type="table"}).

The 5-year overall survival rates for the elderly and middle-aged groups were 52% and 59%, respectively, and this difference was not statistically significant (*P*=0.139; [Figure 1](#f1-cmar-10-2581){ref-type="fig"}). Multivariable analyses revealed that TNM stage, disease-free interval, and number of metastases independently predicted overall survival ([Tables 4](#t4-cmar-10-2581){ref-type="table"} and [5](#t5-cmar-10-2581){ref-type="table"}). The 5-year disease-free survival rates for the elderly and middle-aged groups were 45% and 49%, respectively, and this difference was not statistically significant (*P*=0.090; [Figure 2](#f2-cmar-10-2581){ref-type="fig"}). Multivariable analyses revealed that disease-free interval and preoperative carcinoembryonic antigen levels independently predicted disease-free survival ([Tables 6](#t6-cmar-10-2581){ref-type="table"} and [7](#t7-cmar-10-2581){ref-type="table"}). Age did not independently predict overall or disease-free survival.

Discussion
==========

Increasing life expectancy is leading to a rise in the surgical treatment of elderly patients with CRLM, and surgical resection of liver metastases is considered safe for these patients. However, elderly individuals have more comorbidities and less cardiopulmonary functional reserve, compared to younger patients, and elderly patients experience relatively high rates of postoperative complications and mortality.[@b5-cmar-10-2581]--[@b8-cmar-10-2581] These factors explain the relatively small proportion of elderly patients in the present study, as well as their higher Charlson comorbidity index and American Society of Anesthesiologists score, compared to middle-aged patients. Interestingly, the patients and their families expressed concern regarding the surgery and a desire for non-surgical CRLM treatments.

The liver receives an abundant supply of blood from the hepatic artery and portal vein, and bleeding is common during open hepatectomy.[@b20-cmar-10-2581]--[@b23-cmar-10-2581] However, it is difficult to control any bleeding and replicate some of the open procedures during LH, which can necessitate conversion to open hepatectomy in up to 12% of cases.[@b10-cmar-10-2581]--[@b15-cmar-10-2581] In the present study, the conversion rate among elderly patients was higher than that among middle-aged patients (7% versus 1%, respectively), and bleeding was the overwhelming reason for conversion to open hepatectomy. These findings may be related to the deterioration of physiological mechanisms (e.g., vascular elasticity) and coagulation function in elderly patients, which makes it difficult to control intraoperative bleeding.[@b24-cmar-10-2581]--[@b26-cmar-10-2581] Thus, only open hepatectomy can ensure patient safety. Although we did not detect any obvious differences in the preoperative platelet counts and coagulation test results, coagulation is a very complicated process that may not be completely described using clinical platelet counts and coagulation tests.

The current guidelines categorize LH based on the extent and complexity as minor hepatectomy, major hepatectomy, and difficult hepatectomy.[@b27-cmar-10-2581] Only minor hepatectomy was performed in the present study, and previous reports have also confirmed that LH generally involves minor hepatectomy,[@b5-cmar-10-2581]--[@b8-cmar-10-2581] with a few reports showing major and difficult hepatectomy. This is likely because major and difficult hepatectomies are inherently difficult to perform using the open approach, and the laparoscopic approach further complicates the surgery. Thus, patients who require major or difficult hepatectomy for CRLM may not be able to benefit from the advantages of laparoscopic surgery. Nevertheless, recent reports have indicated that laparoscopic major and difficult hepatectomy is safe and feasible,[@b28-cmar-10-2581]--[@b31-cmar-10-2581] and our hospital began performing laparoscopic major and difficult hepatectomy in June 2016, based on the accumulated experience with LH. We hope to generate additional data to examine the utility of laparoscopic major and difficult hepatectomy in future studies.

Relatively few elderly patients with CRLM undergo LH because of concerns among surgeons that elderly patients may not be able to tolerate pneumoperitoneum, which can lead to higher intraperitoneal pressure and CO~2~ retention in the blood. These factors can theoretically lead to cardiopulmonary complications, although none of the elderly patients in the present study experienced severe cardiopulmonary complications. Three elderly patients experienced minor lung infections, based on the Clavien--Dindo criteria,[@b32-cmar-10-2581]--[@b35-cmar-10-2581] although they recovered fully after treatment using intravenous antibiotics.

Previous studies have revealed 5-year overall survival rates of 48%--61% and 5-year disease-free survival rates of 43%--58% among elderly patients who underwent hepatectomy for CRLM.[@b36-cmar-10-2581]--[@b38-cmar-10-2581] We observed similar outcomes among our elderly patients, and their outcomes were comparable to those of the middle-aged patients. The predominant cause of death among elderly patients was tumor recurrence, with relatively few deaths caused by non-oncological diseases. Therefore, LH appears to be beneficial when indicated for elderly patients with CRLM and to provide good long-term survival, compared to the outcomes for middle-aged patients. Moreover, elderly patients with CRLM have an extremely poor prognosis after receiving non-surgical treatments.

The present study has two important limitations. First, the retrospective design is associated with known risks of bias, and a prospective randomized controlled trial is needed to confirm that LH is safe and effective for elderly patients with CRLM. Second, we only examined data from a single center with a small sample size, and it is possible that our findings may not generalize to other centers and/or patient groups. The fact that the study failed to find statistical significance between the two groups in survival may be due to the small sample size.

Conclusion
==========

The present study results indicate that LH was not associated with elevated rates of postoperative complications or mortality among elderly patients with CRLM, and that their long-term outcomes were comparable to those of middle-aged patients. Therefore, advanced age is not a contraindication for LH treatment of CRLM.

We sincerely thank our colleagues who participated in this research.
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###### 

Baseline characteristics of the two groups

  Characteristic              Middle-aged group (n=163)   Elderly group (n=78)   *P*-value
  --------------------------- --------------------------- ---------------------- -----------
  Age (years)                 67 (60--69)                 74 (70--78)            0.000
  Gender                                                                         0.616
   Male                       114                         57                     
   Female                     49                          21                     
  Charlson comorbidity                                                           0.027
  index                       130                         52                     
   ≤2                         33                          26                     
   \>2                                                                           
  BMI (kg/m^2^)               22 (18--26)                 21 (17--25)            0.221
  Largest tumor size (cm)     3 (1--5)                    2 (1--4)               0.128
  Tumor number                2 (1--4)                    2 (1--3)               0.200
  Tumor laterality                                                               0.584
   Left                       98                          44                     
   Right                      65                          34                     
  Preoperative CEA level                                                         0.357
   \<5 ng/mL                  65                          36                     
   ≥5 ng/mL                   98                          42                     
  Preoperative chemotherapy   118                         69                     0.005
  Initial colorectal cancer                                                      0.271
  TNM stage                                                                      
   I                          29                          18                     
   II                         50                          25                     
   III                        84                          35                     
  ASA score                                                                      0.000
   I                          92                          21                     
   II                         42                          33                     
   III                        29                          24                     

**Abbreviations:** ASA, American Society of Anesthesiologists; BMI, body mass index; CEA, carcinoembryonic antigen.

###### 

Short-term outcomes of the two groups

  Outcome                                                  Middle-aged group (n=163)   Elderly group (n=78)   *P*-value
  -------------------------------------------------------- --------------------------- ---------------------- -----------
  Surgical procedure                                                                                          0.576
   Left lateral sectionectomy                              11                          7                      
   Sectionectomy                                           51                          28                     
   Wedge resection                                         101                         43                     
  Operative time (min)                                     190 (150--290)              180 (160--260)         0.210
  Estimated blood loss (mL)                                240 (160--410)              260 (180--430)         0.218
  Conversion to open surgery                               2                           6                      0.025
  Blood transfusion                                        9                           4                      0.899
  Patients with postoperative 90-day complications         38                          21                     0.542
  Patients with postoperative 90-day major complications   9                           5                      1.000
  Postoperative hospital stay (days)                       9 (7--23)                   10 (7--32)             0.128
  Postoperative 90-day mortality                           1                           1                      1.000
  Residual tumor (R0/R1/R2)                                163/0/0                     78/0/0                 1.000
  Margin distance (mm)                                     10 (5--25)                  11 (6--28)             0.521

###### 

The follow-up data of the two groups

  Outcome                                Middle-aged group (n=163)   Elderly group (n=78)   *P*-value
  -------------------------------------- --------------------------- ---------------------- -----------
  Tumor recurrence, n                    66                          41                     0.078
   Liver                                 32                          21                     0.201
   Extrahepatic                          25                          14                     0.607
   Both                                  9                           6                      0.713
  Time to recurrence (median, months)    22 (2--45)                  18 (2--42)             0.090
  Mortality                              53                          32                     0.196
   Died of cancer                        48                          29                     0.228
   Died of non-cancer-related diseases   5                           3                      1.000

###### 

Univariate Kaplan--Meier analysis of overall survival

  Variable                         Five-year overall survival   *P*-value
  -------------------------------- ---------------------------- -----------
  Age                                                           0.139
   60--69 years                    59                           
   ≥70 years                       52                           
  Gender                                                        0.201
   Male                            58                           
   Female                          54                           
  Charlson comorbidity index                                    0.087
   ≤2                              61                           
   \>2                             52                           
  ASA score                                                     0.351
   I--II                           59                           
   III                             54                           
  Preoperative CEA level                                        0.106
   \<5 ng/mL                       61                           
   ≥5 ng/mL                        49                           
  TNM stage of colorectal cancer                                0.007
   I--II                           68                           
   III                             43                           
  Disease-free interval                                         0.011
   \<12 months                     42                           
   ≥12 months                      67                           
  Tumor number                                                  0.024
   \<3                             59                           
   ≥3                              48                           
  Tumor laterality                                              0.547
   Left                            56                           
   Right                           51                           

**Abbreviations:** ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.

###### 

Cox proportional hazards model for overall survival

  Variable                                          Hazard ratio (95% CI)   *P*-value
  ------------------------------------------------- ----------------------- -----------
  Charlson comorbidity index ≤2 versus \>2          1.205 (0.651--1.558)    0.128
  TNM stage of colorectal cancer I--II versus III   1.981 (1.258--3.854)    0.021
  Disease-free interval ≥12 versus \<12 months      1.610 (1.378--2.873)    0.015
  Tumor number \<3 versus ≥3                        1.500 (1.258--1.870)    0.041

###### 

Univariate Kaplan--Meier analysis of disease-free survival

  Variable                         Five-year overall survival   *P*-value
  -------------------------------- ---------------------------- -----------
  Age                                                           0.090
   60--69 years                    49                           
   ≥70 years                       45                           
  Gender                                                        0.210
   Male                            51                           
   Female                          46                           
  Charlson comorbidity index                                    0.089
   ≤2                              52                           
   \>2                             44                           
  ASA score                                                     0.181
   I--II                           51                           
   III                             45                           
  Preoperative CEA level                                        0.021
   \<5 ng/mL                       58                           
   ≥5 ng/mL                        41                           
  TNM stage of colorectal cancer                                0.032
   I--II                           54                           
   III                             46                           
  Disease-free interval                                         0.008
   \<12 months                     39                           
   ≥12 months                      59                           
  Tumor number                                                  0.128
   \<3                             51                           
   ≥3                              44                           
  Tumor laterality                                              0.224
   Left                            52                           
   Right                           44                           

**Abbreviations:** ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.

###### 

Cox proportional hazards model for disease-free survival

  Variables                                         Hazard ratio (95% CI)   *P*-value
  ------------------------------------------------- ----------------------- -----------
  Age 60--69 versus ≥70 years                       1.328 (0.544--1.698)    0.210
  Charlson comorbidity index ≤2 versus \>2          1.187 (0.749--1.584)    0.267
  TNM stage of colorectal cancer I--II versus III   1.415 (0.879--1.874)    0.089
  Disease-free interval ≥12 versus \<12 months      1.874 (1.215--2.001)    0.036
  Preoperative CEA level \<5 versus ≥5 ng/mL        1.740 (1.418--2.108)    0.028

**Abbreviation:** CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis.
